We submit herewith Unaudited Financial Results for the Quarter ended June 30, 2026 together with Limited Review Report.

CIN L33112MP1985PLC003039 RAAJ MEDISAFE INDIA LIMITED Regd. Office: REG. OFF. : 75/2 AND 3, INDUSTRIAL AREA, MAKSI ROAD, UJJAIN,456010 (M.P.)Email: raajmedisafe@gmail.com, Website: www.raajmedisafeindia.com August 12, 2026 BSE Ltd Phiroze Jeejeebhoy Towers, Dalal Street, MUMBAI-400001 SCRIP CODE: 524502 Dear Sir, SUB. UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th 2026. Pursuant to clause 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 we enclose herewith- a. Limited Review Report for the Quarter ended June 30, 2026 issued by Statutory Auditors of the company. b. Unaudited Financial Results of the Company for the quarter ended on June 30, 2026. c. Segment Unaudited Financial Results of the Company for the quarter ended on June 30, 2026. The above Statements/reports have been reviewed by audit committee and taken on record by the Board of Directors of the Company in its meeting held on August 12, 2026 Kindly take the same on record. Thanking you, Yours faithfully, FOR RAAJ MEDISAFE INDIA LIMITED ARPIT BANGUR Chairman and MANAGING DIRECTOR DIN: 02600716 Encls: As stated Report on Review of Interim Financial Information Board of Directors of Raaj Medisafe India Limited Maksi Road, Ujjain We have reviewed the accompanying statement of Standalone unaudited Financial Results of the Raaj Medisafe India Limited (CIN: L33112MP1985PLC003039) for the quarter ended 30th June, 2026 and the year to date results for the period commencing from 1st April, 2026 to 30th June, 2026 being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This statement is the responsibility of the Company’s management and has been approved by the Board of Directors in charge. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Engagements to review Financial Statements” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Cont.. 2 Page 2 Based on our review conducted as above, as supplemented by Notes forming part of accounts, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For GDK & Associates Chartered Accountants ICAI Firm Registration No. : 002159C Place: Indore Dated: August 12th, 2026 CA Anand Jain Partner Membership No.: 427705 UDIN: 26427705USAOOL5501 RAAJ MEDISAFE INDIA LIMITED REG. OFF. : 75/2 AND 3, INDUSTRIAL AREA, MAKSI ROAD, UJJAIN (M.P.) - 456010 Email : info@medisafeindia.com; Contact : 0734-2518989/2513349 CIN-L33112MP1985PLC003039 Website : www.raajmedisafeindia.com UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 [Amount - ₹ Lakhs (except EPS)] Particulars For the For the For the For the Quarter ended Quarter ended Quarter ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) I Revenue from Operations 2,945.91 2,507.68 1,582.70 8,001.46 II Other Income 15.45 28.16 0 .56 56.31 III TOTAL INCOME (I + II) 2,961.36 2,535.84 1,583.26 8,057.77 IV EXPENSES (a) Cost of Materials Consumed 2,129.76 1,541.13 1,222.24 5,268.56 (b) Purchase of Stock-in-Trade - - - - (c) Manufacturing and Operating Costs - - - - (d) Changes in Inventories of Finished Goods, Work-In-Progress and Traded Goods (90.60) 133.08 ( 215.00) ( 120.97) (e) Employee Benefits Expense 165.22 108.39 113.25 510.34 (f) Finance Costs 86.36 107.97 68.13 396.32 (g) Depreciation and Amortisation Expense 70.67 62.50 48.64 204.16 (h) Other Expenses 335.82 454.15 199.94 1,167.13 TOTAL EXPENSES (IV) 2,697.23 2,407.22 1,437.20 7,425.54 V Profit before exceptional and extraordinary items and tax (III-IV) 264.13 128.62 146.06 632.23 VI Exceptional items - - - - VII Profit before Tax (V-VI) 264.13 128.62 146.06 632.23 VIII Tax Expense: Current Tax 49.42 105.53 - 105.53 Current Tax Expense relating to prior years - - - - Deferred Tax 17.34 345.72 - 345.73 Total Tax Expenses 66.76 4 51.25 - 451.26 IX Net Profit/(Loss) for the Period (VII-VIII) 197.37 (322.63) 146.06 1 80.97 X Other Comprehensive Income A. (i) Items that will not be reclassified subsequently to profit or loss - - - - (ii) Income tax relating to items that will not be reclassified subsequently to profit or loss - - - - B. (i) Items that will be reclassified subsequently to profit or loss - - - - (ii) Income tax relating to items that will be reclassified subsequently to profit or loss - - - - XI Total Comprehensive Income for the Period (IX+X) 197.37 (322.63) 146.06 180.97 XII Paid-up equity share capital 1,642.43 1,642.43 1,318.10 1,642.43 (Face Value Rs.10 Per Share) . XIII Reserves excluding Revaluation Reserves 3,228.95 3,031.58 1,373.68 3,031.58 XIV Earnings per share (of Rs.10/- each) (not annualized) : (a) Basic 1.20 (1.96) 1 .11 1.37 (b) Diluted 1.20 (1.96) 1 .11 1.37 Notes : 1 The above financial results for the Quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of Company in its meeting held on 12th August, 2026. 2 The Statutory Auditors of the Company have carried out a Review of the financial results for the Quarter ended on 30th June, 2026. The Management has exercised necessary due diligence to ensure that such financial results provide a true & fair view of the affairs of the Company. 3 The Financial Results are prepared in accordance with Indian Accounting Standards ('Ind AS') notified under section 133 of the Companies Act, 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015 (as amended). The Company is primarily engaged in the business of Plastic Products and Hygiene which constitute reportable segments in accordance with Ind AS 108 "Segment reporting". 4 The previous period figures have been regrouped/ reclassified wherever necessary to make them comparable with the current period’s figures. 5 Reserve excluding Revaluation Reserve has been updated. For & On behalf of Board of Directors For Raaj Medisafe India Limited Place :- Ujjain Arpit Bangur Dated :- 12/08/2026 Chairman and Managing Director (DIN-02600716) Page 1 of 1 RAAJ MEDISAFE INDIA LIMITED REG. OFF. :75/2 AND 3, INDUSTRIAL AREA, MAKSI ROAD, UJJAIN (M.P.) - 456010 CIN-L33112MP1985PLC003039 Website : www.raajmedisafeindia.com STANDALONE SEGMENT WISE REVENUE, RESULTS AND SEGMENT ASSETS & LIABILITIES FOR THE QUARTER ENDED 30TH JUNE, 2026 (Amount - ₹ in Lakhs) Particulars For the For the For the For the Quarter ended Quarter ended Quarter ended Year ended 30-06-2026 31-03-2026 30-06-2025 31-03-2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Segment Revenue (a) Plastics Division 2,112.00 1,534.62 1 ,162.56 5 ,403.21 (b) Hygiene Division 851.17 1,001.22 422.90 2 ,654.57 Total 2,963.17 2,535.84 1 ,585.46 8 ,057.78 Less: Inter Segment Revenue 1.81 1.48 2.20 5.36 Gross Revenue from sale of Products & Services 2,961.36 2,534.36 1 ,583.26 8 ,052.42 2 Segment Results (a) Plastics Division 350.74 105.96 178.18 6 26.70 (b) Hygiene Division 31.08 172.22 77.47 5 98.85 ---------------------------- ------------- [Showing first 8,000 characters — download PDF for full document]